ArticleHypertension research : official journal of the Japanese Society of Hypertension2025
Long-term risk of cardiovascular mortality according to age group and blood pressure categories of the latest guideline.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2026Trial
- The impact of the "Ibaraki Zero-Hypertension Action" campaign on improving health awareness among residents and blood pressure management.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Differences in ambulatory blood pressure and heart rate between smoking and abstinence periods among current smokers: A systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- PRDM16 modulates aspects of cell cycle dynamics and maturation in human iPSC-derived cardiomyocytes.Stem cell reports · 2026Article
- Reply to: Blood Pressure-Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real-World Data Analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Comprehensive evaluation of the triglyceride glucose index (TyG) and body roundness index (BRI) on cardiovascular disease risk prediction: a 9-year prospective cohort study in Chinese middle-aged and older adults.Cardiovascular diabetology · 2026Article
- Current hypertension epidemiology and contemporary approaches using the "Real-World Evidence Cycle" framework.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Association between the atherogenic index of plasma and prehypertension or hypertension among adults in Fujian, China: a population-based cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Understanding clinical inertia in hypertension management: clues from real-world data.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- The JSH Morning Hypertension Eradication Program Project.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Delayed treatment initiation as one of the crucial factors in clinical inertia: lessons from a real-world database research.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Association Between Antihypertensive Treatment Discontinuation and the Development of Intracerebral Hemorrhage in Japanese Patients With Hypertension: The LIFE Study.Journal of the American Heart Association · 2025Article
- Carnitine metabolism in hypertensive heart failure.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the association between the latest blood pressure (BP) classification and cardiovascular disease (CVD) mortality risk, using data from 70,570 individuals across 10 Japanese cohorts. Participants were stratified by age (40-64 and 65-89 years) and antihypertensive treatment use. BP was classified according to the 2019 Japanese Society of Hypertension Guidelines. During a follow-up period of approximately 10 years, 2304 CVD deaths occurred. Cox models demonstrated that CVD mortality risk increased stepwise with the BP category, with this association being especially pronounced in patients aged 40-64 years, where the Grade I hypertension group showed the highest population-attributable fraction (PAF). When the treated participants were included in the hypertension group, the overall PAF for CVD mortality was 41.1%. Similar patterns were observed for CVD subtype mortality risk, with hypertension showing particularly high PAFs for intracerebral hemorrhage. These findings highlight the importance of early-stage prevention and management of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.